{"id":"immunosuppression-reduction-modification-intravenous-immunoglobulin","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Rejection episodes"},{"rate":null,"effect":"Infection risk"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The strategy involves tapering or modifying standard immunosuppressive regimens (such as calcineurin inhibitors or antimetabolites) while simultaneously providing IVIG to enhance immune regulation and reduce rejection risk. IVIG contains pooled human antibodies that can suppress autoreactive B and T cells, promote regulatory T cell expansion, and modulate complement activation, potentially allowing safer reduction of toxic immunosuppressive drugs.","oneSentence":"This therapeutic approach reduces immunosuppressive medication burden while administering intravenous immunoglobulin to modulate immune tolerance in transplant recipients.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:21.030Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prevention with reduced immunosuppression burden"}]},"trialDetails":[{"nctId":"NCT05325008","phase":"PHASE3","title":"A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients","status":"RECRUITING","sponsor":"The University of Queensland","startDate":"2023-08-18","conditions":"BK Viremia, Kidney Transplant Infection, Kidney Transplant Failure and Rejection","enrollment":280},{"nctId":"NCT05365672","phase":"PHASE2","title":"Clinical Trial With Donor Modified Immune Cells in Living Donor Kidney Transplantation","status":"RECRUITING","sponsor":"TolerogenixX GmbH","startDate":"2022-05-04","conditions":"Kidney Transplantation","enrollment":126},{"nctId":"NCT02686619","phase":"PHASE3","title":"Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-11","conditions":"Renal Transplantation","enrollment":237}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Human immunoglobulin"],"phase":"phase_3","status":"active","brandName":"Immunosuppression reduction/modification + intravenous immunoglobulin","genericName":"Immunosuppression reduction/modification + intravenous immunoglobulin","companyName":"The University of Queensland","companyId":"the-university-of-queensland","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This therapeutic approach reduces immunosuppressive medication burden while administering intravenous immunoglobulin to modulate immune tolerance in transplant recipients. Used for Organ transplant rejection prevention with reduced immunosuppression burden.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}